Filtering by:
Immunotherapy2018 in Review: New Cancer Drug Approvals
In 2018, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
Study Supports Immunotherapy for Treating Triple-Negative Breast Cancer
A study by an international group of researchers has found for the first time that a combination of immunotherapy and chemotherapy can extend lives of women with triple-negative breast cancer.
FDA Approves Libtayo (Cemiplimab) for a Type of Skin Cancer
The US Food and Drug Administration (FDA) has approved Libtayo (cemiplimab) to treat people with advanced squamous cell carcinoma of the skin.
Nobel Prize Awarded to Cancer Immunotherapy Researchers
The 2018 Nobel Prize in Physiology or Medicine has been awarded jointly to two cancer immunotherapy researchers, James P. Allison, PhD, of The University of Texas MD Anderson Cancer Center, and Dr. Tasuku Honjo of Kyoto University in Japan.
FDA Approves Opdivo (Nivolumab) for Small Cell Lung Cancer
The US Food and Drug Administration had approved the immunotherapy drug Opdivo (nivolumab) to treat people with small cell lung cancer (SCLC).
Researchers Report Advances in Lung Cancer Immunotherapy
Scientists presenting at the American Association for Cancer Research Annual Meeting in Chicago have found new and promising ways to use immunotherapy to treat people with some types of non-small cell lung cancer (NSCLC).
FDA Approves Imfinzi (Durvalumab) for Some Lung Cancers
The US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for people with stage III (3) non-small cell lung cancer who are not able to be treated with surgery to remove their tumor, and whose cancer has not gotten worse after they received chemotherapy along with radiation (chemoradiation).
New Cancer Drug Approvals From 2017
In 2017, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.